Bedside Rounds

Major bleeding on anticoagulants (reversal): workup and management

Major bleeding on an anticoagulant: stop the drug, resuscitate, find and control the source, and reverse when bleeding is life-threatening or in a critical site (intracranial, airway, pericardial, retroperitoneal). Choose the reversal agent by drug and timing of last dose.

Working diagnosis Adult · US guidelines Draft · awaiting physician review
Tailor to a patient with AI Bedside calculators Report an error

01Orient

What's new in the evidence

  • Andexanet alfa (Andexxa) was withdrawn from the US market in December 2025; 4-factor PCC is now the practical first-line agent for factor Xa inhibitor–associated major bleeding
  • ANNEXA-I (2024): andexanet improved hemostatic efficacy in Xa-inhibitor ICH but increased thrombotic events, including ischemic stroke
  • AHA/ASA 2022 ICH guideline: lower PCC dose (10–20 units/kg) when INR is 1.3 to <2.0

Differential diagnoses

  1. Intracranial hemorrhage (can't miss)
  2. GI bleeding
  3. Retroperitoneal or muscle hematoma
  4. Hemopericardium, hemothorax
  5. Supratherapeutic anticoagulation (drug interactions, AKI, liver disease)
  6. Underlying lesion unmasked by anticoagulation (cancer)

02Assess

Risk scores and decision tools

  • Major bleeding definition: critical site, hemodynamic instability, or Hb drop ≥2 g/dL / ≥2 units transfused
  • Time and dose of last anticoagulant; creatinine clearance
  • HAS-BLED for restarting decisions

Key history questions

  • Which anticoagulant, dose and time of last dose
  • Indication for anticoagulation (mechanical valve, recent VTE, AF)
  • Antiplatelets and NSAIDs
  • Kidney and liver disease; new interacting drugs
  • Head trauma, headache, neurological symptoms

Examination findings

  • Hemodynamics, GCS
  • Site-specific signs (abdominal, flank, thigh swelling)
  • Neurological exam

03Investigate

Initial investigations

  • CBC, PT/INR, aPTT, fibrinogen, BMP, type and crossmatch
  • Anti-Xa level calibrated to the drug if available
  • Thrombin time (dabigatran: normal TT excludes significant levels)
  • CT head for headache, trauma or neuro change; CT angiography for active bleeding

Advanced investigations

  • Endoscopy or interventional radiology for source control
  • Repeat INR 15–30 minutes after PCC

04Treat

Immediate management

  • Stop the anticoagulant and antiplatelets; local measures and source control
  • Warfarin: 4F-PCC by INR (25 units/kg for INR 2–<4, 35 for 4–6, 50 for >6) or fixed 1500–2000 units, plus vitamin K 10 mg IV
  • Apixaban or rivaroxaban: 4F-PCC 2000 units fixed (or 25–50 units/kg)
  • Dabigatran: idarucizumab 5 g IV; hemodialysis if unavailable

First-line treatment

  • Unfractionated heparin: protamine 1 mg per 100 units given in the past 2–3 hours (max 50 mg)
  • Enoxaparin within 8 hours: protamine 1 mg per 1 mg enoxaparin (partial reversal)
  • Activated charcoal if an oral Xa inhibitor or dabigatran was taken within 2–4 hours
  • Transfuse RBCs, platelets and cryoprecipitate as indicated

Second-line treatment

  • Tranexamic acid only in trauma or selected bleeding sites; not in GI bleeding
  • Restart anticoagulation once hemostasis is secure: often 7 days after GI bleeding, 1–4 weeks after ICH depending on risk

Specialist referrals

  • Neurosurgery for ICH
  • Gastroenterology or IR for GI bleeding
  • Hematology and pharmacy for reversal

05Disposition

Admission criteria

  • Any major or critical-site bleeding
  • Need for reversal or transfusion

Safe discharge criteria

  • Minor bleeding controlled, stable Hb, clear anticoagulation plan

Follow-up timing

  • Review the anticoagulation indication and restart plan before discharge; follow up within 1–2 weeks

Patient instructions

  • Carry an anticoagulant card; report bleeding or black stools

Monitoring

  • Hb every 6–12 hours
  • Neuro checks in ICH
  • Watch for thrombosis after reversal

Clinical pearls and pitfalls

  • PCC carries a thrombotic risk; use it for real major bleeding, not for an isolated high INR
  • High INR without bleeding: hold warfarin, give oral vitamin K 2.5–5 mg if INR >10
  • Reversal does not treat the bleeding source

RefGuidelines and landmark evidence

For education only. Typical adult starting points; confirm doses against renal function, allergies, interactions and your institution's protocols. Not a substitute for clinical judgment or senior review.

Calculators for this workup

HAS-BLEDOakland score
Acetaminophen overdoseAcute abdominal painAcute aortic dissectionAcute cholangitis and choledocholithiasisAcute decompensated heart failureAcute diverticulitisAcute dizziness and vertigoAcute ischemic stroke and TIAAcute kidney injuryAcute pancreatitisAcute pericarditisAdrenal crisisAlcohol withdrawalAlcohol-associated hepatitisAnaphylaxisAnemia in hospitalized adultsAsthma exacerbationAtrial fibrillation with rapid ventricular responseBacterial meningitisCellulitisChest painClostridioides difficile infectionCommunity-acquired pneumoniaCOPD exacerbationDecompensated cirrhosis (ascites, SBP, hepatic encephalopathy)Deep vein thrombosisDelirium / acute confusionDiabetic foot infection and osteomyelitisDiabetic ketoacidosisFebrile neutropeniaFirst seizure and status epilepticusHypercalcemiaHyperglycemia in hospitalized adultsHyperkalemiaHypernatremiaHyperosmolar hyperglycemic state (HHS)Hypertensive emergencyHypoglycemiaHypokalemiaHyponatremiaInfective endocarditisLower GI bleedMalignant spinal cord compressionNSTEMI and non-ST-elevation ACSOpioid overdose and opioid use disorderPulmonary embolismPyelonephritis and complicated UTIRhabdomyolysisSepsisShortness of breathSickle cell vaso-occlusive crisisStaphylococcus aureus bacteremiaSymptomatic bradycardia and heart blockSyncopeThrombocytopenia (including TTP, HIT and ITP)Thunderclap headache (rule out subarachnoid hemorrhage)Thyroid stormTumor lysis syndromeUpper GI bleed